Health TrialsbyHealthPanel

Clinical trials

4

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

This Study Evaluates the Diagnostic Performance and Safety of 68Ga-NYM032 PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer.

This study evaluates the diagnostic performance and safety of 68Ga-NYM032 PET/CT imaging in patients with suspected recurrence of prostate cancer.

Participants needed: 232
Trial details
Phase: Phase 3Age: 18+Biological sex: MaleType: InterventionalSponsor: Norroy Bioscience Co., LTDUpdated: Sep 15, 2026Locations: 2
Eligibility criteria

Patient is male and aged >18 years old. [+5]

Participants who have previously participated in other interventional clinical t... [+4]

Read more
Status: Not yet recruiting

Study to Evaluate the Efficacy and Safety of 177Lu-NYM032 Injection in Participants With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)

The primary objective of this study is to compare overall survival (OS) in patients with progressive PSMA-positive mCRPC who receive 177Lu-NYM032 in addition to best supportive/best standard of care versus patients treated with best supportive/best standard of care alone.

Participants needed: 600
Trial details
Phase: Phase 3Age: 18+Biological sex: MaleType: InterventionalSponsor: Norroy Bioscience Co., LTDUpdated: Aug 31, 2026
Eligibility criteria

Patient must be male and aged ≥18 years old. [+20]

Any systemic anti-cancer therapy (e.g. chemotherapy, immunotherapy or biological... [+27]

Read more
Status: Recruiting

Investigating the Safety and Diagnostic Performance of 68Ga-NYM032 Injection PET/CT in Men With Newly Diagnosed Prostate Cancer.

The investigators are imaging patients with newly diagnosed prostate cancer using a new Positron Emission Tomography (PET) imaging agent (68Ga-NYM032) in order to evaluate the safety and diagnostic performance.

Participants needed: 365
Trial details
Phase: Phase 3Age: 18+Biological sex: MaleType: InterventionalSponsor: Norroy Bioscience Co., LTDUpdated: Aug 17, 2026Locations: 2
Eligibility criteria

Patient is male and aged >18 years old. [+3]

1. Participants who have previously participated in other interventional clinica...

Read more
Status: Not yet recruiting

Evaluation of Safety, Pharmacokinetics, Distribution，Radiation Safety and Sensitivity/Specificity of PET/CT Imaging With 68Ga-NYM096 in Participants With IRM

68Ga-NYM096 is a carbonic anhydrase IX (CAIX)-targeted imaging agent that is under clinical development as a non-invasive diagnostic imaging agent for the detection of clear cell renal cell carcinoma (ccRCC). The Phase 1 study is to evaluate the safety, pharmacokinetics, radioactivity distribution, radiation safety and preliminary diagnostic performance in participants with indeterminate renal masses (IRM)

Participants needed: 20
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Norroy Bioscience Co., LTDUpdated: Aug 17, 2026
Eligibility criteria

Imaging evidence of a single indeterminate renal mass on contrast-enhanced CT or... [+5]

A biopsy procedure only (rather than partial or radical nephrectomy) planned for... [+8]

Read more